Similar articles for PMID: 23229814

Year	Number of Results
2001	2
2004	3
2005	2
2006	1
2007	3
2008	3
2009	6
2010	3
2011	19
2012	16
2013	22
2014	17
2015	7
2016	4
2018	2
2019	2
2020	4
2021	2
2022	2
2023	1
2024	0

1

Omalizumab: NICE to USE you, to LOSE you NICE.

Bush A, Pavord ID. Bush A, et al. Thorax. 2013 Jan;68(1):7-8. doi: 10.1136/thoraxjnl-2012-202969. Thorax. 2013. PMID: 23229814 No abstract available.

2

Omalizumab under 12 years old: real-life practice.

Pite H, Gaspar Â, Paiva M, Leiria-Pinto P. Pite H, et al. Allergol Immunopathol (Madr). 2013 Mar-Apr;41(2):133-6. doi: 10.1016/j.aller.2012.01.008. Epub 2012 May 3. Allergol Immunopathol (Madr). 2013. PMID: 22560014 No abstract available.

3

Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.

Weheba IM, Abdelsayed AM, Arnaout RK, Zeitouni MO, Mobaireek KF, AlHarthi TB, Mobeireek AF. Weheba IM, et al. Ann Saudi Med. 2018 Nov-Dec;38(6):439-444. doi: 10.5144/0256-4947.2018.439. Ann Saudi Med. 2018. PMID: 30531179 Free PMC article.

4

Omalizumab in patients with severe asthma: the XCLUSIVE study.

Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C. Schumann C, et al. Clin Respir J. 2012 Oct;6(4):215-27. doi: 10.1111/j.1752-699X.2011.00263.x. Epub 2011 Aug 9. Clin Respir J. 2012. PMID: 21740532 Clinical Trial.

5

NICE guidance on omalizumab for severe asthma.

Diaz RA, Charles Z, George E, Adler AI. Diaz RA, et al. Lancet Respir Med. 2013 May;1(3):189-90. doi: 10.1016/S2213-2600(13)70066-3. Epub 2013 Apr 24. Lancet Respir Med. 2013. PMID: 24429120 No abstract available.

6

Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.

Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Pace E, et al. J Asthma. 2011 May;48(4):387-92. doi: 10.3109/02770903.2011.561512. Epub 2011 Mar 11. J Asthma. 2011. PMID: 21391878

7

Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Maselli R. Pelaia G, et al. Curr Drug Targets. 2015;16(2):171-8. doi: 10.2174/1389450116666141219122157. Curr Drug Targets. 2015. PMID: 25523898 Review.

8

Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.

Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM. Tzortzaki EG, et al. Pulm Pharmacol Ther. 2012 Feb;25(1):77-82. doi: 10.1016/j.pupt.2011.11.004. Epub 2011 Dec 3. Pulm Pharmacol Ther. 2012. PMID: 22155001

9

[Retrospective analysis of omalizumab in patients with severe allergic asthma].

Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R. Padullés Zamora N, et al. Farm Hosp. 2013 Sep-Oct;37(5):399-405. doi: 10.7399/FH.2013.37.5.728. Farm Hosp. 2013. PMID: 24128103 Free article. Spanish.

10

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Kornmann O, et al. Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18. Pulm Pharmacol Ther. 2014. PMID: 24657236 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year